Elon H C van Dijk1, Rosa L Schellevis2, Maaike G J M van Bergen2, Myrte B Breukink2, Lebriz Altay3, Paula Scholz3, Sascha Fauser3, Onno C Meijer4, Carel B Hoyng2, Anneke I den Hollander5, Camiel J F Boon6, Eiko K de Jong2. 1. Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands. 2. Department of Ophthalmology, Donders Institute of Brain, Cognition, and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands. 3. Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany. 4. Division of Endocrinology and Metabolism, Department of Medicine, Leiden University Medical Center, Leiden, the Netherlands5Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands. 5. Department of Ophthalmology, Donders Institute of Brain, Cognition, and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands6Department of Human Genetics, Donders Institute of Brain, Cognition, and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands. 6. Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands7Department of Ophthalmology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Abstract
Importance: Chronic central serous chorioretinopathy (cCSC) is a chorioretinal disease with unknown disease etiology. The glucocorticoid receptor and the mineralocorticoid receptor, 2 glucocorticoid-binding receptors, might be involved in the pathogenesis of cCSC. Objective: To assess the association of functional variants and haplotypes in the glucocorticoid receptor (NR3C1) and mineralocorticoid receptor (NR3C2) genes with cCSC. Design, Setting, and Participants: In this case-control genetic association study, 336 patients with cCSC and 1314 unaffected controls, collected at 3 university medical centers from September 1, 2009, to May 1, 2016, underwent KASP genotyping for selected variants in NR3C1 (rs56149945, rs41423247, and rs6198) and NR3C2 (rs2070951 and rs5522). Main Outcomes and Measures: Genetic associations of 3 NR3C1 variants and 2 NR3C2 variants with cCSC. Results: Among the 336 patients (274 men and 62 women; mean [SD] age, 52 [10] years), after correction for multiple testing, rs2070951 in the NR3C2 gene was significantly associated with cCSC (odds ratio, 1.29; 95% CI, 1.08-1.53; P = .004). Moreover, the GA haplotype of single-nucleotide polymorphisms rs2070951 and rs5522 in NR3C2 conferred risk for cCSC (odds ratio, 1.39; 95% CI, 1.15-1.68; P = .004), whereas the CA haplotype decreased risk for cCSC (odds ratio, 0.72; 95% CI, 0.60-0.87; P < .001). Three known variants in NR3C1 that alter the activity of the glucocorticoid receptor (rs56149945, rs41423247, and rs6198) were not associated with cCSC. Conclusions and Relevance: In this study, the variant rs2070951 and the GA haplotype in NR3C2 were associated with an increased risk for cCSC. Results of this genetic study support a possible role for the mineralocorticoid receptor in the pathogenesis of cCSC. Since these haplotypes have previously been associated with perceived stress, this study provides a clue to bridging clinical risk factors for cCSC to underlying genetic associations.
Importance: Chronic central serous chorioretinopathy (cCSC) is a chorioretinal disease with unknown disease etiology. The glucocorticoid receptor and the mineralocorticoid receptor, 2 glucocorticoid-binding receptors, might be involved in the pathogenesis of cCSC. Objective: To assess the association of functional variants and haplotypes in the glucocorticoid receptor (NR3C1) and mineralocorticoid receptor (NR3C2) genes with cCSC. Design, Setting, and Participants: In this case-control genetic association study, 336 patients with cCSC and 1314 unaffected controls, collected at 3 university medical centers from September 1, 2009, to May 1, 2016, underwent KASP genotyping for selected variants in NR3C1 (rs56149945, rs41423247, and rs6198) and NR3C2 (rs2070951 and rs5522). Main Outcomes and Measures: Genetic associations of 3 NR3C1 variants and 2 NR3C2 variants with cCSC. Results: Among the 336 patients (274 men and 62 women; mean [SD] age, 52 [10] years), after correction for multiple testing, rs2070951 in the NR3C2 gene was significantly associated with cCSC (odds ratio, 1.29; 95% CI, 1.08-1.53; P = .004). Moreover, the GA haplotype of single-nucleotide polymorphisms rs2070951 and rs5522 in NR3C2 conferred risk for cCSC (odds ratio, 1.39; 95% CI, 1.15-1.68; P = .004), whereas the CA haplotype decreased risk for cCSC (odds ratio, 0.72; 95% CI, 0.60-0.87; P < .001). Three known variants in NR3C1 that alter the activity of the glucocorticoid receptor (rs56149945, rs41423247, and rs6198) were not associated with cCSC. Conclusions and Relevance: In this study, the variant rs2070951 and the GA haplotype in NR3C2 were associated with an increased risk for cCSC. Results of this genetic study support a possible role for the mineralocorticoid receptor in the pathogenesis of cCSC. Since these haplotypes have previously been associated with perceived stress, this study provides a clue to bridging clinical risk factors for cCSC to underlying genetic associations.
Authors: Nienke van Leeuwen; Silja Bellingrath; E Ronald de Kloet; Frans G Zitman; Roel H DeRijk; Brigitte M Kudielka; Stefan Wüst Journal: Psychoneuroendocrinology Date: 2010-11-20 Impact factor: 4.905
Authors: Eiko K de Jong; Myrte B Breukink; Rosa L Schellevis; Bjorn Bakker; Jacqueline K Mohr; Sascha Fauser; Jan E E Keunen; Carel B Hoyng; Anneke I den Hollander; Camiel J F Boon Journal: Ophthalmology Date: 2014-11-06 Impact factor: 12.079
Authors: Elon H C van Dijk; Michiel F Nijhoff; Eiko K de Jong; Onno C Meijer; Aiko P J de Vries; Camiel J F Boon Journal: Graefes Arch Clin Exp Ophthalmol Date: 2016-07-08 Impact factor: 3.117
Authors: R Sacconi; G Baldin; A Carnevali; L Querques; A Rabiolo; G Marchini; F Bandello; G Querques Journal: Eye (Lond) Date: 2018-01-05 Impact factor: 3.775
Authors: Rosa L Schellevis; Elon H C van Dijk; Myrte B Breukink; Lebriz Altay; Bjorn Bakker; Bobby P C Koeleman; Lambertus A Kiemeney; Dorine W Swinkels; Jan E E Keunen; Sascha Fauser; Carel B Hoyng; Anneke I den Hollander; Camiel J F Boon; Eiko K de Jong Journal: JAMA Ophthalmol Date: 2018-10-01 Impact factor: 7.389
Authors: Danial Mohabati; Rosa L Schellevis; Elon H C van Dijk; Sascha Fauser; Anneke I den Hollander; Carel B Hoyng; Eiko K De Jong; Suzanne Yzer; Camiel J F Boon Journal: Retina Date: 2020-09 Impact factor: 3.975
Authors: Rosa L Schellevis; Elon H C van Dijk; Myrte B Breukink; Jan E E Keunen; Gijs W E Santen; Carel B Hoyng; Eiko K de Jong; Camiel J F Boon; Anneke I den Hollander Journal: Mol Genet Genomic Med Date: 2019-02-06 Impact factor: 2.183